Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours by Kelleher, Fergal C & Thomas, David M
REVIEW Open Access
Molecular pathogenesis and targeted
therapeutics in Ewing sarcoma/primitive
neuroectodermal tumours
Fergal C Kelleher
1,2* and David M Thomas
2
Abstract
Background: Ewing sarcoma/PNET is managed with treatment paradigms involving combinations of
chemotherapy, surgery, and sometimes radiation. Although the 5-year survival rate of non-metastatic disease
approaches 70%, those cases that are metastatic and those that recur have 5-year survival rates of less than 20%.
Molecularly targeted treatments offer the potential to further improve treatment outcomes.
Methods: A PUBMED search was performed from 1997 to 2011. Published literature that included the topic of the
Ewing sarcoma/PNET was also referenced.
Results: Insulin-like growth factor-1 receptor (IGF-1R) antagonists have demonstrated modest single agent efficacy
in phase I/II clinical trials in Ewing sarcoma/PNET, but have a strong preclinical rationale. Based on in vitro and
animal data, treatment using antisense RNA and cDNA oligonucleotides directed at silencing the EWS-FLI chimera
that occurs in most Ewing sarcoma/PNET may have potential therapeutic importance. However drug delivery and
degradation problems may limit this therapeutic approach. Protein-protein interactions can be targeted by
inhibition of RNA helicase A, which binds to EWS/FLI as part of the transcriptional complex. Tumour necrosis factor
related apoptosis inducing ligand induction using interferon has been used in preclinical models. Interferons may
be incorporated into future chemotherapeutic treatment paradigms. Histone deacetylase inhibitors can restore
TGF-b receptor II allowing TFF-b signalling, which appears to inhibit growth of Ewing sarcoma/PNET cell lines in
vitro. Immunotherapy using allogeneic natural killer cells has activity in Ewing sarcoma/PNET cell lines and
xenograft models. Finally, cyclin dependent kinase inhibitors such as flavopiridol may be clinically efficacious in
relapsed Ewing sarcoma/PNET.
Conclusion: Preclinical evidence exists that targeted therapeutics may be efficacious in the ESFT. IGF-1R
antagonists have demonstrated efficacy in phase I/II clinical trials, although predicting responses remains a
challenge. The future treatment of Ewing sarcoma/PNET is likely to be improved by these scientific advances.
Introduction
Ewing sarcoma/PNET is a high grade malignancy in
which approximately 75% of cases are localised at diag-
nosis, and 25% are initially metastatic [1-3]. The Surveil-
lance Epidemiology and End Results (SEER) program
reported an annual incidence rate of 2.93 cases/
1,000,000 in the interval from 1973 to 2004 [3]. This
low incidence has impaired the ability of clinicians to
conduct prospective randomised controlled trials as
frequently as is desirable. The general treatment para-
digm for ESFT is chemotherapy with intercalated loco
regional management with surgery with or without
radiation treatment for patients with localized disease.
The current overall disease free survival rate for meta-
static disease is 25% and residual or recurrent Ewing
sarcoma/PNET has a 10% overall survival rate. The
Childhood Cancer Survivor Study issued a report in
2009 on late recurrence in paediatric cancers on a retro-
spective cohort of 12,795 survivors that had not
recurred in the first 5 years post diagnosis. The greatest
risk factor for late recurrence on multivariate analysis
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and 4.5 respectively. In the case of Ewing sarcoma/
PNET, the cumulative incidence of late recurrence at 10
years was 9.4%, rising to 13% at 20 years [4]. For long-
term survivors of childhood Ewing sarcoma/PNET
(defined as patients that survived ≥ 5 years from diagno-
sis), the overall cumulative mortality of Ewing Sarcoma/
PNET survivors was 25% when followed 25 years post
diagnosis. Disease recurrence/progression accounted for
60.3% of deaths. Subsequent malignant neoplasms occur
in 9% of survivors, and the risk of second cancers (parti-
cularly thyroid cancer, sarcoma and breast cancers) was
increased by exposure to radiotherapy. There was also
an increased risk of chronic health conditions (70.7% of
survivors versus 33.7% of siblings) and infertility (the
relative rate of pregnancy in survivors versus siblings
was 0.65) [5]. There is an urgent need to improve cure
rates for localized, metastatic and recurrent disease,
while concurrently decreasing treatment related morbid-
ity. Emergent targeted therapeutics offer many exciting
possibilities in this disease and this publication concerns
new molecular treatments for Ewing sarcoma/PNET
tumours and evolving treatment paradigms that include
targeted therapeutics. The field of improving treatment
outcomes for patients with Ewing sarcoma/PNET by
molecular therapeutics is hindered by the low frequency
of Ewing sarcoma/PNET, the age demographics and
technical obstacles such as therapeutics based on siRNA
and cDNA oligonucleotides having drug delivery and
degradation problems. Many of these problems poten-
tially can be surmounted by increased collaboration
between preclinical researchers and physicians caring for
patients with Ewing sarcoma/PNET tumours.
Ewing sarcoma/PNET tumours: an overview
Ewing sarcoma, peripheral primitive neuroectodermal
tumours and Askin tumour of the chest wall belong to
the Ewing sarcoma/PNET category of tumours.
Although Ewing sarcoma/PNET tumours frequently are
of osseous origin, 10% of cases of Ewing sarcoma/PNET
tumours arise in extra skeletal soft tissues. It may arise
from bone generating mesoderm however it does
express neuroectodermal proteins. An emergent consen-
sus favours it to be mesodermally derived [6]. Studies
have found that inhibition of EWS-FLI expression in
patient derived Ewing sarcoma/PNET cells lines causes
these cells to adopt a mesenchymal stem cell phenotype
[7,8]. There is a need for improving diagnostic tests to
identify Ewing sarcoma. Many of the clinical, morpholo-
gical and immunophenotypic characteristics of Ewing/
PNET tumours are shared by other diseases such as
small cell osteosarcoma and mesenchymal chondrosar-
coma. Finding EWSR1 translocation can be very useful
for deciding upon therapeutic management but an
e x p a n s i o ni nm o l e c u l a rd i s e ase identifiers is required
particularly when one considers the combinatorial diver-
sity among chromosomal breakpoints in Ewing sar-
coma/PNET tumours.
Ewing sarcoma/PNET affects children’s, adolescents
and young adults with most cases occurring in the sec-
ond and third decades of life. The median age at diag-
nosis ranges from 13 to 19 years in studies not
restricted to paediatric recruitment. Interestingly adoles-
cents and young adults (AYA) fare more poorly than
children diagnosed with this disease, and is a subject for
research. A 2003 study of standardized chemotherapeu-
tic regimens in Ewing sarcoma/PNET had a 5 year sur-
vival rate for children less than 10 years of age of 70%
compared with 60% for 10 to 17 year olds and 44% for
18 years and older. The reasons for poorer survival in
the AYA demographic are complex including biologic
heterogeneity, physician experience in differing treat-
ment centres and stagnant improvements in the overall
AYA cancer survival statistics. It also is the case that
adults tend to present with a higher frequency of meta-
static disease and primary sites in a central or pelvic
location all of which are associated with a more unfa-
vourable prognosis.
The past decade has seen significant improvements in
outcomes for patients with Ewing sarcoma/PNET [9].
The European Intergroup Cooperative Ewing’s sarcoma
study group evaluated prognostic factors in Ewing’s
tumour/PNET of bone in 975 patients with a median
follow-up of 6.6 years. Metastasis at diagnosis conferred
a 5 year relapse free survival (RFS) of 22% versus 55%
for patients without initial metastasis (P < .0001). In the
group with metastasis at diagnosis, multivariate analysis
showed that site (axial or other) and age cohort (≥ 15
years versus < 15 years) had a significant effect on
relapse free survival [10]. Other established prognostic
factors outlined in the Clinical Recommendations
devised by the European Society of Medical Oncology
are tumour volume, serum lactate dehydrogenase, axial
location and age greater than 15 years [11].
Members of the Ewing sarcoma/PNET family of
tumours are characterized by rearrangements involving
the EWS gene on chromosome 22q12 and fusion part-
ners from the ETS oncogene family, most frequently
FLI1 on chromosome 11q24 (85%) as demonstrated in
Figure 1, or ERG on chromosome 21q22 (10%). The
EWS gene also has 3 other ETS family gene partners
leading to the chimeric gene transcripts. The five most
common gene rearrangements are detailed in table 1
however other rarer fusions have been described.
Ninety-five percent of ESFT have fusion of the central
exons of the EWSR1 gene (Ewing Sarcoma Breakpoint
Region 1) to the central exons of an ETS gene family
member and fusion occurs between the NH2 end of the
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partner. In Ewing sarcoma/PNET tumours it was pre-
viously considered that one particular rearrangement
was specific for the malignancy and that no molecular
shift occurs during progression. However a case has
been described of a patient, in whom two separate
Ewing sarcoma/PNET tumours arose after a 56 month
remission interval, initially involving a EWS/ERG fusion
transcript followed by a EWS/FLI1 fusion [12]. As
Ewing sarcoma/PNET tumours have variable breakpoint
locations in the involved genes, there is heterogeneity in
fusion RNA and protein architecture. The effect of
EWS-ETS fusion type on disease progression in Ewing
sarcoma/PNET tumours was evaluated prospectively
from the co-operative Euro-E.W.I.N.G. 99 trial [13].
Variants in the genomic breakpoint location lead to the
transcription of varying RNA’s. In most cases rearrange-
ments occur with EWS intron 7 or 8: FLI1 introns 5 or
4 leading to either fusion of EWS intron 7 to Fli1 exon
6 (type I fusion [EF1]) documented in 51% of cases or
exon 5 (type 2 fusion [EF2]) recorded in 27% of cases.
This prospective study found no correlation with
fusion type and prognosis. This refuted two previous
smaller retrospective studies that suggested a correlation
between fusion type and Ewing sarcoma/PNET prog-
nosis [14,15]. Overall, current evidence does not support
the use of translocation type for prognostication in
Ewing sarcoma/PNET. This finding is also substantiated
b yaC h i l d r e n ’s Oncology Group prospective study pub-
lished in 2010 [16]. In that study the association of type
1 EWS-FLI1 (fusion between exons 7 of EWS and 6 of
FLI1) and non type 1 transcript translocations were cor-
related with disease characteristics, event free survival
and overall survival. It was found that 89% of identified
transcripts were EWS-FLI1 and of that cohort 58.8%
were type 1. The event free survival at 5 years and over-
all survival did not show a clinical disadvantage to non-
Figure 1 Diagram of t(11;22)(q24;q12) and the EWS-FLI1 gene fusion. Adapted from; Enrique de Alava, William L. Gerald, Biology of
Sarcoma/Primitive Neuroectodermal Tumor Family, Journal of Clinical Oncology, Vol 18, Issue 1(January), 2000: 204.
Table 1 Common Ewing sarcoma/PNET family of tumours
chimeric fusion gene translocations: Most frequently
implicated chimeric fusion gene translocations.
Genes Translocation
EWS FLI1 t(11;22)(q24;q12)
EWS ERG t(21;22)(q22;q12)
EWS ETV1 t(7;22)(p22;q12)
EWS E1AF t(17;22)(q12;q12)
EWS FEV t(2;22)(q33;q12) *
*Other ETS family partners: ETV4, PATZ1 (~5%), FUS-ERG (< 1%)
(Primer of the Molecular Biology of Cancer. Cancer Principles and Practice.
Chapter 26; Sarcomas, p 334 Table 26.1).
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gested by retrospective studies. The analysis was
restricted to patients with localised tumours that were
diagnosed subsequent to 1994 and treated with COG
protocols. It was postulated that advances in treatment
in particular the routine inclusion of IE into Ewing sar-
coma/PNET protocols eliminated the prognostic disad-
vantage of non-type 1 fusions.
Chemotherapy in Ewing sarcoma/PNET
Initial treatment
An overview of current cytotoxic management options
in Ewing sarcoma/PNET is important as most emergent
molecularly targeted therapeutics probably will be incor-
porated into existing treatment paradigms. The Chil-
dren’s Cancer Group and the Paediatric Oncology
Group initiated a trial (National Cancer Institute, proto-
col INT-0091) on patients 30 years old or younger with
Ewing sarcoma, primitive neuroectodermal tumour of
bone, or primitive sarcoma of bone [17]. The study
included patients with both localised and metastatic dis-
ease and the findings were published in 2003. Patients
were randomly assigned to receive standard chemother-
apy with doxorubicin, vincristine, cyclophosphamide,
and dactinomycin or experimental therapy with these
four drugs alternating with treatment with ifosfamide
and etoposide. In patients without metastatic disease the
5 year EFS rate in the experimental arm was 69% versus
54% in the standard treatment cohort. Furthermore the
overall 5 year survival rate for the experimental treat-
ment was 72% versus 61% for the standard regimen
with a relative risk of death of 1.6 for the standard treat-
ment. The European Intergroup Cooperative Ewing Sar-
coma Study-92 (EICESS-92) published in 2008,
investigated whether cyclophosphamide has a similar
efficacy to ifosfamide in standard risk patients and
whether the addition of etoposide improves survival in
high risk patients [18]. Cyclophosphamide appears to
have a similar effect on event free survival and overall
survival as ifosfamide, but also increased toxicity. The 3
year EFS difference observed was 6.8%, and there was
an EFS hazard ratio of 0.80 for localised disease and
0.96 for metastatic disease favouring the etoposide con-
taining regimen. This was consistent with the finding of
the National Cancer Institute/Intergroup Ewing Tumour
Group trial INT-0091. These studies therefore suggest
that the addition of ifosfamide and etoposide to a stan-
dard regimen does not affect the outcome for patients
with metastatic disease.
Dose intensification has been studied. A Children’s
Oncology Group study that was published in abstract
form compared vincristine, doxorubicin and cyclopho-
sphamide alternating with ifosfamide and etoposide
treatment every 2 weeks with that of treatment every 3
weeks. The interval compression group had an improved
event free survival at 3 years (76% vs. 65% 3, P = 0.028
[19]. The Children’s Oncology Group also in 2009
reported a study National Cancer Institute protocol
INT-0154 (Children’s Cancer Group 7942/Pediatric
Oncology Group 9354) which opened to institution
between dates in 1995 and 1998. In this study the dose
intensification of alkylating agents did not improve EFS
and overall survival for patients with Ewing sarcoma/
PNET [20]. Whether dose intensification may benefit a
subgroup at particularly high risk remains an area of
active research. Outcomes are significantly worse for
patients with metastatic disease at diagnosis, prompting
testing of dose-intensified regimens in this setting. The
Euro-EWING 99 R3 study published in 2010 consisted
of a single arm study of 281 patients with high-risk dis-
ease that received six cycles of vincristine, ifosfamide,
doxorubicin, and etoposide, one cycle of vincristine, dac-
tinomycin, and ifosfamide, local treatment (surgery and/
or radiotherapy), and high-dose busulfan-melphalan fol-
lowed by autologous stem-cell transplantation [19]. The
estimated 3-year EFS from the start of high dose treat-
ment/stem cell transplant was 45% for 46 children
younger than 14 years. Overall this study has a 3-year
EFS of 27% and an OS of 34%.
Relapsed disease
Relapsed Ewing sarcoma/PNET is generally regarded as
an incurable disease. A 2005 study reported that 49% of
patients achieved a partial or complete response to sec-
ond-line treatment, with a median duration of response
of 27 months [21]. The five-year OS for relapsed
patients was 23%. Multivariate analysis found a reduced
risk of death following response to second line treat-
ment (relative risk; RR 0.14), if the relapse free interval
was greater than 24 months (RR 0.29) and for those
receiving high dose treatment (RR 0.26). Despite this,
the role of high dose chemotherapy with autologous
stem cell transplantation in relapsed disease is uncertain.
A 1995 report from the EBMT solid tumour registry
that evaluated the impact of megatherapy in a subgroup
of children in second complete remission with high risk
Ewings/PNET tumours found they had actuarial EFS of
32% at 5 years [22]. While high dose therapy may be
useful in some patients as consolidation treatment for
patients with Ewing sarcoma/PNET in second complete
remission, most reports are non-randomised studies of
patients with responsive disease [23]. The role of high
dose therapy remains a subject for research.
Newer cytotoxic agents have entered clinical use.
Camptothecin derivatives are effective in Ewing sar-
coma. While single agent treatment with irinotecan and
topotecan has shown little efficacy in phase I and II stu-
dies of patients with refractory disease, combinations
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tecan, topotecan with cyclophosphamide and high dose
ifosfamide [24]. Most studies are limited by small
patient numbers and the tendency to combined evalua-
tion of patients with refractory and relapsed disease
leading to study population heterogeneity. The combina-
tion of irinotecan and temozolamide was retrospectively
reported on a 20 patient series with recurrent/refractory
disease from Memorial Sloan Kettering, NY. There were
5c o m p l e t ea n d7p a r t i a lr e s p o n s e s( 6 3 %o v e r a l l
response rate). Median time to progression was 8.3
months for patients with recurrent/progressive ES and
for the subset with recurrent ES it was 16.2 months
[25]. In another study the combination of cyclophospha-
mide and topotecan for patients with refractory or
relapsed Ewing tumours was reported on 54 patients by
German investigators. 32.6% had a partial response and
26.5% had stable disease. Of 19 relapsed patients that
attained a complete response, 52.6% maintained remis-
sion. After a median follow-up of 23.1 months 25.9% of
patients were in continuous complete or partial remis-
sion [26]. Lastly, high-dose ifosfamide was described in
a study in which 33 patients with relapsed or advanced
disease and 4 patients that had progression during
neoadjuvant treatment, with a 34% overall response rate
[27]. Finally, trabectedin has been evaluated in meta-
static Ewing sarcoma/PNET patients progressing after
standard chemotherapy yielding a 10.3% partial response
rate, while 13.7% of patients experienced stable disease.
The 6 month progression-free survival was 25% [28].
New treatment strategies in Ewing sarcoma/PNET
tumours
The National Cancer Institute in the United States are
conducting clinical trials in Ewing sarcoma as selected
trial that in particular utilise targeted molecular thera-
peutic strategies are documented in table 2. There is an
urgent need for novel therapeutic strategies, particularly
for patients with advanced disease at diagnosis, or who
relapse following definitive treatment. The following sec-
tions describe a range of targeted and other approaches
which are currently under investigation.
EWS-FLI1 Gene Silencing
The t (11; 22) EWS-FLI1 translocation is seen in 85% of
cases of Ewing sarcoma, while the t (11; 22) EWS-WT1
translocation is seen in Desmoplastic small round cell
tumours. Indeed the same 5’ portions of EWSR1 that
are implicated in Ewing sarcoma are fused to WT1 in
this distinct tumour entity. The NH2 terminus of the
EWS gene fuses with the COOH end of the ETS gene
partner in 95% of Ewing sarcoma family of tumours ren-
dering it an attractive therapeutic target. EWS-FLI1
expression can be reduced by antisense oligonucleotides,
antisense RNA (expressed from a vector) and small
interfering RNA delivered by nanoparticles. EWS-FLI1
elimination through antisense cDNA and siRNA causes
prolonged survival of ESFT xenograft bearing mice
[21,29,30]. However, therapeutics based on siRNA and
cDNA oligonucleotides have inherent bioavailability and
administration problems, and are not readily applicable
to the clinical setting. EWS-FLI1 furthermore lacks a
fixed structure and the EWS-FLI1 protein product lacks
enzymatic activity and is not associated with constitutive
activation of a tyrosine kinase. Therefore designing ther-
apeutics that target EWS-FLI1 protein interactions is
more therapeutically feasible rather than targeting the
EWS-FLI1 protein itself. For example, RNA helicase A
(RHA) binds to EWS-FLI1 as part of the EWS-FLI1
transcriptional complex that includes RNA polymerase
II, cyclic AMP response element-binding protein and
RHA. Small molecule blockade with YK-4-279 of the
oncogenic protein EWS-FLI1 interaction with RNA heli-
case A inhibits growth of Ewing sarcoma by inducing
apoptosis and may also regulate the cell cycle protein,
cyclin D1 [31,32]. One study combining EWS-FLI-1
antisense oligonucleotide and rapamycin efficiently
induced the apoptotic death of EWS cells in culture
through a caspase-dependent apoptotic process that
involved restoration of the TGF b-induced pro-apoptotic
pathway in vivo [33].
An alternative strategy involves targeting downstream
signalling molecules. Researchers at the University of
Alabama found that EWS-FLI1 induced manic fringe
(MNFG) renders NIH3T3 cells tumorigenic [34]. MNFG
is a member of the Fringe gene family required for
establishing the dorsoventral wing boundary in Droso-
phila wing development, and plays a key role in the
Notch pathway. Conceptually, it is plausible that g-secre-
tase inhibitors targeting the Notch pathway may have
clinical efficacy in Ewing sarcoma/PNET. A Canadian
study found that Ewing sarcomas express Notch recep-
tors, ligands and HES1 a target gene of the Notch path-
way [35]. Furthermore, inhibition of Notch signalling
induced neural differentiation in Ewing sarcoma cell
lines however inhibition of Notch was associated with
only a small change in tumour growth potential.
A separate study from INSERM France and UCLA
combined siRNA technique with microarray technology
to find genes regulated by EWS/FLI1 [36]. The authors
found two functional classes of regulated genes. The
first group were extracellular matrix components includ-
ing collagen and lysyl-oxidase enzymes. The second
functional cluster included genes regulating signal trans-
duction pathways including negative regulators of IGF-1,
STAT, Wnt and MAPK. This study particularly found
evidence that the constitutive activation of the IGF-1
p a t h w a yi nE w i n gs a r c o m aw as partly attributable to
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Study Title Phase
protocol’s
ID
Sponsor/lead
organisations
Important points Primary objective
Phase I/II partially randomised
study of Hedgehog antagonist
GDC-0449 in combination with g-
Secretase Inhibitor RO4929097 in
patients with advanced or
metastatic sarcoma
Phase I/II
MSKCC-
10049
10-049,8406,
NCT01154452
Sponsor: NCI
Lead Organisation:
Memorial Sloan-
Kettering Cancer
Centre
Age: 18 and over
Advanced sarcoma (Phase Ib)
Advanced, metastatic sarcoma
(Phase II)
Expected enrolment (EE)120
(i) To determine maximum
tolerated dose of RO4929097 when
combined with GDC-0449 in
patients with advanced sarcoma
(Phase Ib).
(ii) To assess progression free
survival (PFS) of patients with
advanced, metastatic sarcoma
treated with RO4929097 with or
without GDC-0449.
Phase II study of AuroraA Kinase
Inhibitor MLN8237 in paediatric
patients with recurrent or refractory
solid tumours or leukaemia
Phase II
COG-
ADVL0921
ADVL0921
NCT01154816
Sponsor: NCI
Lead Organisation:
Children’s Oncology
Group
Age: 1-21 years
Entry criteria includes patients with
histological confirmed Ewing
sarcoma/peripheral primitive
neuroectodermal tumour
EE 190
Assess objective response rate in
paediatric patients
Phase II study of Cixutumumab in
patients with relapsed or refractory
solid tumours
Cixutumumab: A fully human IgG1
monoclonal antibody directed
against IGF-1R *
Phase II
COG-
ADVL0821
ADVL0821
NCT00831844
Sponsor: NCI
Lead Organisation:
Children’s Oncology
Group
Age: 6 months-30 years
Entry criteria includes patients with
histological confirmed Ewing
sarcoma/peripheral primitive
neuroectodermal tumour
EE140
(i) Assess response rate
(ii) Toxicity
Secondary outcome:
Relationship between tumour
expression of IGF-I, IGF-II, and IGF-
IR and response*
Phase II study of MK8669 in
patients with metastatic bone or
soft-tissue sarcoma (8669-030)
MK8669 is a small molecule mTOR
inhibitor and rapamycin analogue.
mTOR is a serine/threonine kinase
located downstream of the PI3K/
Akt signalling pathway
Phase II Sponsor:
Pharmaceutical/
Industry
Trial sites located in
Japan
Age: 13 and over
Exclusion criteria include CNS
metastasis (unless successfully
treated), prior treatment with
rapamycin or rapamycin analogues,
on-going therapeutic toxicity from
anticancer treatment, intercurrent
or historic disease that may
potentially confound results
Evaluation of MK 8669 when
administered as maintenance
therapy to patients with metastatic
bone or soft-tissue sarcoma in
Japan
IMC-A12 in combination with
temsirolimus (CCI-779) in patients
with advanced cancers
Phase I
2007-0595
MDA-2007-
0595
8109
NCT00678223
NCT00678769
Sponsor: NCI
Lead organisation: M.
D. Anderson Cancer
Centre, University of
Texas
Age: 16 and over
3-6 participants each dose level of
IMC-A12 in combination with
temsirolimus
(i) To establish the highest
tolerable dose combination of IMC-
A12 and temsirolimus that can be
given to patients with advanced or
metastatic cancer.
(ii) Establish drug safety.
Tolerability of dose scheduling
Biomarker studies incorporated
A phase I study of NK cell infusion
following allogeneic peripheral
blood stem cell transplantation
from related or matched unrelated
donors in paediatric patients with
solid tumours and leukaemia’s
Phase I
110073
11-C-0073
NCT01287104
NCI Age: 4-35 years
Paediatric solid tumours (if ESFT
must have ultra-high risk ESFT)
Re: EWS;
(i) If at initial diagnosis has bone or
bone marrow metastasis may be
enrolled if completed standard
front line therapy (SFLT) that
includes vincristine,
cyclophosphamide, adriamycin,
ifosfamide and etoposide (ii)
Patients with recurrence of tumour
at any site less than 1 year after
completing SFLT or with
subsequent recurrence any time
after completing SFLT (iii) Patients
with progressive or persistent
disease while receiving standard
front line chemotherapy
(i) To determine the safety,
effectiveness, and immune system
response of giving NK white blood
cells to individuals who have
received allogeneic HSCT.
(ii) To identify possible treatment
related side effects.
Background: Based on laboratory
evidence NK cells following
allogeneic PBSCT may have a
beneficial anti-cancer therapeutic
effect
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Ewing sarcoma IGFBP3 based therapeutics may partly
obviate therapeutic resistance to IGF-1R antagonists, for
instance the overall response rate of only 12.4% seen in
the phase I/II study involving figitumumab [37-39].
Overall repression of IGFBP-3 appears to be important
in the development of Ewing sarcoma/PNET and EWS-
FLI1 can bind the IGFBP-3 promoter in-vitro and in-
vivo and repress its activity [34,40].
IGF-1R antagonists
The insulin-like growth factor 1 receptor (IGF-1R) is a
transmembrane receptor with tyrosine kinase activity
when it binds its ligands IGF-I and IGF-II. After ligand
binding the phosphatidylinositol 3’ kinase, RAS-MAPK
and JAK-STAT (Janus kinase and signal transducers and
activators of transcription) pathways are activated caus-
ing cellular proliferation and survival [41]. All Ewing
sarcoma/PNET cells express IGF-1R and are stimulated
by IGF-1 in autocrine loops [42]. IGF-1 also is stored in
the bone matrix and is potentially liberated by tumour
induced osteolysis, a paracrine effect [43]. IGF-1R has
no described mutations, is occasionally amplified but is
frequently over expressed. Epidemiologically it is notable
that ESFT usually occur in the 2nd and 3rd decades of
life with a peak incidence at age 15 when growth
hormone mediated IGF-1 production would be expected
to be maximal. Experimentally, the IGF-1R pathway is
necessary for malignant transformation when the cells
are transfected with EWS/FLI1 cDNA [44]. In Ewing
sarcoma; it appears that increased autocrine stimulation
may be due to increased IGF1 ligand and IGF-1R over-
expression, as well as repression of of the inhibitory pro-
tein, IGFBP3 [45,46].
Therapeutics directed against IGF1R include either
antibodies (for example, IgG1: R1507 and AMG479;
IgG2: figitumumab) or else small molecule tyrosine
kinase inhibitors. Striking clinical responses for most
IGF-1R inhibitors in Ewing sarcoma patients have been
documented [40,45]. A phase I expansion cohort study
of figutumumab in 29 patients with Ewing sarcoma and
other sarcomas of whom 16 had Ewing sarcoma found
two patient’s (both of whom had Ewing sarcoma) that,
had objective responses (one complete response, one
partial response). Eight patients had disease stabilization
of whom 6 had Ewing sarcoma/PNET lasting 4 to 16
months [47]. In a separate phase I/II study of figitumu-
mab in patients with refractory Ewing sarcoma/PNET
and other sarcomas, 16 patients with Ewing were
entered onto the phase 1 portion and no dose limiting
toxicities attributable to figitumumab emerged at the
prescribed dose escalated cohorts of 20 or 30 mg/kg IV
Table 2 Selected National Cancer Institute, U.S. (Continued)
Studies of Temozolamide in
combination with topotecan in
refractory and relapsed paediatric
solid tumours
Phase II
CSET 2008/
1378
NCT
00918320
Lead organization:
Institut Gustave
Roussy
Age: 6 months - 20 years.
Eligibility criteria include:
Confirmed paediatric solid tumour,
relapsed/refractory tumours in
which SFLT has failed, not more
than 2 lines of prior chemotherapy,
CT/MRI measurable disease
To determine that the combination
of topotecan and temozolamide is
effective in the treatment of
relapsed and refractory solid
neuroblastoma and other
paediatric solid tumours.
PCI-24781 in combination with
doxorubicin to treat sarcoma
A broad-spectrum phenyl
hydroxamic acid inhibitor of
histone deacetylase (HDAC).
Inhibits several isoforms of HDAC
causing accumulation of highly
acetylated histones and induction
of chromatin remodelling. It also
inhibits homologous
recombination (HR) activity by
inhibiting the expression of RAD51
Phase I, II Lead organisation/
Sponsor
Massachusetts
General Hospital
Age: 18 years and over
PCI-24781 is considered to regulate
genes involved in tumour growth.
To determine safety and maximum
tolerated dose of PCI-24781 that
can be safety given with
doxorubicin (phase I) and the the
safety and efficacy of PCI-24781
when combined with doxorubicin
(phase II) in patients with advanced
sarcomas.
Study in localised and
disseminated Ewing sarcoma
Phase III Lead organisation/
sponsor:
Medizinische Klinik
und Poliklinik A-
Universitaetsklinikum
Muenster, Germany
Age: 4-50 years
EWING 2008 is a joint protocol of
European and North American
Ewing sarcoma study groups. Open
to all patients diagnosed with
Ewing sarcomas, localised or
metastatic, who are considered
eligible for neoadjuvant
chemotherapy.
Standard Risk R1: Randomised trial
High Risk R2: Randomized trial
Very High Risk R3: Randomized trial
Refer to NCI website for full study
details
Clinical trials in Ewing sarcoma www.cancer.gov Entered search terms: Ewing sarcoma/PNET. Search, restricted to treatment.
*ASCO Annual meeting Chicago, 2011. The combination of Cixutumumab and temsirolimus was well tolerated in a study of 17 Ewing sarcoma patients. Prolonger
tumour reduction in excess of 6 months and one complete response was seen in 29% of heavily pre-treated patients with Ewing’s sarcoma/PNET (Poster
Discussion Session Board #23).
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stage of the trial, 15 had a partial response and 25 had
stable disease. Median PFS and OS were 1.9 and 8.9
months respectively. Patients with pre-treatment IGF-1
levels greater than 110 ng/ml (n = 79) had a median
overall survival of 10.5 months whereas those with base-
line IGF-1 levels less than 110 ng/ml (n = 19) had a
median overall survival of 4.5 months with an estimated
OS hazard ratio between the two populations of 0.354.
This preliminary data set suggests that figitumumab
may be efficacious in treating Ewing sarcoma/PNET
[39]. A phase I study of the fully human monoclonal
antibody AMG479 was published in 2008 [34]. That
study established that AMG 479 can be safely adminis-
tered at a dose of 20 mg/kg IV Q2W. Of 53 enrolled
patients, 12 had a diagnosis of Ewing/PNET. Despite
being primarily a pharmacodynamic and pharmacoki-
netic study it is notable that one patient that had pre-
viously received 5 courses of chemotherapy with a
histologic diagnosis of Ewing/PNET had a rapid
response to AMG 479 with a partial response on posi-
tron emission tomography-CT on day 8. A complete
response (CR) occurred by day 57. The patient remains
in sustained CR at 30 months. Molecular genetics found
that the patient had the t (11; 22) (q24; q12) transloca-
tion and the EWS-FLI1 type 1 fusion product (exon 7/
exon 6) and immunohistochemistry of a lung metastasis
showed IGF-1R expression.Af u r t h e rp a t i e n tw i t ha
EWS-FLI 1 type III fusion product (exon 10/exon 6)
had a partial response but discontinued therapy. Ten
additional Ewing/PNET patients were enrolled in the
expansion phase but none experience a response.
It is plausible that inhibition of IGF-1R ameliorates
the negative feedback of IGF-1 on growth factor secre-
tion at the pituitary level. It has been shown that growth
hormone negative feedback is mediated by somatome-
din-C at the hypothalamic and pituitary levels [48].
Additionally observed toxicities included hyperglycae-
mia, hypothyroidism, grade 3 thrombocytopenia (n = 8/
53) and grade 3 transaminitis (n = 1) as well as grade 1
and 2 toxicities. Hyperglycaemia is a commonly
observed adverse effect from IGF-1R targeted therapeu-
tics, and it was observed that despite the fact that the
extracellular domain of IGF-1R and the insulin receptor
(INSR) are approximately 50% identical AMG 479 did
not bind or block insulin binding to the INSR in non-
clinical studies [49,50].
A MD Anderson initiated phase I study of R1507, a
monoclonal antibody to the insulin like growth factor
receptor-1 (IGF1R), was conducted on 37 patients with
advanced solid tumours. Nine of the patients entered
had a diagnosis of Ewing sarcoma. Efficacy results were
not the main study end-points however 2 patients with
Ewing sarcoma had durable partial responses of 11.5
and > 26 months each and 2 had stable disease [51]. In
a phase II trial of 125 patients with recurrent or refrac-
tory Ewing sarcoma/PNET treated with R1507, 18
patients had a CR or PR (14.4%). Twelve patients
responded for at least 6 weeks with a median duration
of response of 25 weeks. Median survival was 7.6
months [52]. It also should be mentioned that inhibition
of the IGF-1R receptor pathway by a small molecule
IGF-1R antagonist (ADW742) was examined alone or
combined with imatinib, doxorubicin and vincristine in
Ewing tumour/PNET cell lines. Treatment reduced cel-
lular proliferation, induced G1 arrest and apoptosis as
well as leading to down regulation of IGF-1R, AKT, and
mTOR phosphorylation [53]. 113 patients were treated
in a multi-centre phase II trial of R1507 in patients with
recurrent or refractory Ewing sarcoma/PNET. Median
age was 25 with 57% of cases having a primary bone
tumour and 43% an extra skeletal primary site. Overall
complete/partial response rate was 10%. Median dura-
tion of response was 29 weeks and median survival was
7.6 months. Of 11 responses observed 10 were in
patients that had presented with primary osseous
tumours [54].
In addition to monoclonal antibody targeting of IGF-
1R and small molecule tyrosine kinase inhibitors a third
method to treat Ewing sarcoma based on IGF-1R
involves increasing circulating insulin-like growth factor
binding protein 3 (IGFBP-3) levels. Investigators at
INSERM Paris found that IGFBP-3 was strongly induced
upon treating Ewing sarcoma/PNET cells with EWS/
FLI-1-specific small interfering RNAs and IGFBP-3 has
been considered to be a potential anticancer molecule in
Ewing sarcoma [36]. Exogenous IGFBP-3 inhibited EWS
growth in monolayers and anchorage-independent con-
ditions [55,56]. Insulin like growth factor binding pro-
tein 3 is a potential anticancer therapeutic in Ewing
sarcoma. A low level of IGFBP-3 was observed in a
panel of cell lines or clinical samples indicating constitu-
tive activation of the IGF-1 pathway in Ewing sarcoma.
It was observed that the mechanism of action of IGFBP-
3 was considered to be essentially attributable to IGF-1
sequestration. Systemic administration of IGFBP-3 may
be associated with putative toxicities like insulin resis-
tance and osteoporosis. Systemic toxicities may be partly
obviated by local administration, and as 90% of Ewing
sarcoma/PNET as skeletal and a third of Ewing sar-
coma/PNET metastasis are in a skeletal location this is
therapeutically advantageous were IGFBP-3 to be used
therapeutically.
Based on accumulated data from phase I and II clini-
cal trials up to 2011, only approximately 10% of cases of
Ewing sarcoma/PNET respond to IGF-1R directed ther-
apeutics. Mechanisms of drug resistance and predictors
of medication sensitivity need to be refined for IGF-1R
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evaluated putative IGF-1R downstream pathways in
Ewing sarcoma cells, and showed constitutive activation
of Erk1/2 and Akt important mediators of the MAPK
and PI3-K pathways [57]. The authors found that both
the MEK/MAPK inhibitors (PD98059 and U0126) and
PI3K inhibitor (LY294002) decrease Ewing sarcoma/
PNET cell survival by induction of G1 blockade. MEK/
MAP blockade also increases Ewing sarcoma/PNET cell
sensitivity to doxorubicin and reduces the cells migra-
tory ability. Another potential mechanism of resistance
to IGF-1R targeted therapies is enhanced insulin recep-
tor (IR) -A homodimer formation and IGF-2 production
[58]. Resistance cells can switch from IGF-1/IGF-1R to
IGF2/IR-A dependency to continue activation of AKT
and ERK1/2, proliferation and metastasis (the IR can
exist in two isoforms that differ at the carboxy terminus
of the a subunit by 12 amino acids termed, IR-A and
IR-B). Resistance to IGF-1R directed therapeutics is
partly mediated by increased insulin receptor signalling.
In cell line variants resistant to IGF-1R antagonism
there was exclusive expression of the IR-A isoform and
increased activation of ERK1/2, AKT and STAT-3
which correlate with the malignant phenotype. It
appears treatment efficacy should be evaluated in rela-
tion to the malignant cellular IR-A:IGF-1R ratio.
Tumours with a low IGF-1R:IR ratios are unlikely to
have a good chance of benefiting from IGF-1R directed
therapeutics. Overall the field of insulin like growth fac-
tors in physiologic processes and cancers of different
subtypes including Ewing sarcoma/PNET is a fascinat-
ing, important and rapidly evolving topic. Excellent
comprehensive reviews of the subject are available [59].
Finally there also is the theoretical potential for combin-
ing IGR1R inhibitors with other drugs such as mTOR
inhibitors with the prospect of enhanced treatment
efficacy.
mTOR inhibition
A key component of the PI3K pathway is mTOR. Trans-
f o r m a t i o nb yP I 3 Ka n dA K Td o w n s t r e a mo fI G F - 1a n d
PDGF is dependent on the phosphorylation and activa-
tion of the 40S ribosomal protein S6 kinase (p70
S6K)
and the phosphorylation of 4E-binding protein by
mTOR. Different types of EWS/FLI1expresse differing
levels of total and phosphorylated mTOR protein. The
concept of treating malignancies with mTOR inhibitors
arises from increased mTOR activity in inherited condi-
tions such as tuberous sclerosis that has increased fre-
quency of multi-organ hamartomas and renal cell
cancers (approximately 2.5%). Tuberous sclerosis is
caused by inactivating mutations of either of the TSC1
and TSC2 tumour suppressor genes that encode the
cytoplasmic TSC1 (hamartin) and TSC2 (tuberin)
proteins respectively. These proteins interact with and
inhibit mTOR [60]. Investigators treating angiomyolipo-
mas in tuberous sclerosis complex, lymphangioleiomyo-
matosis or PEComas with sirolimus found evidence of
clinical activity [61,62]. The use of rapamycin as a cyto-
static treatment has been evaluated in Ewing sarcoma/
PNET cell lines with heterogeneous EWS/FLI1 fusion
genes. Rapamycin was found to inhibit cell line prolif-
eration by causing G1 phase arrest with concurrent
down regulation of EWS/FLI1 protein and restoration of
expression of TGF-b type 2 receptor [63]. TGF-b type 2
receptor is transcriptionally repressed in Ewing sarcoma
cells, and exposure to rapamycin resulted in a marked
increase in TGF-b receptor 2 mRNA in the cell lines
tested with concomitant increased susceptibility to TGF-
b inhibition of growth.
Targeting the KIT oncoprotein
Expression of KIT protein, mutational status of the kit
gene exons 9, 11, 13, and 17, exons 12 and 18 of the
PDGFRA gene, and exon 12 of the PDGFRB gene was
evaluated in 71 cases of Ewing sarcomas [64]. Twenty
seven (38%) were immunohistochemically positive for
KIT protein but activating mutations in c-kit were
f o u n di no n l y2o ft h e7 1c a s e s( 2 . 6 % ) ,w i t h i ne x o n9 .
No activating mutations in the PDGFRA and PDGFRB
genes were found but PDGFRA exon 18 polymorphisms
were documented. Evidently c-kit activating mutations
were found not to be coincident with KIT protein
expression in Ewing sarcoma/PNET [60]. Imatinib has
clinical efficacy is another sarcoma dermatofibrosarcoma
protuberans; that tumour usually has a t(17:22) translo-
cation and a response to imatinib is seen in 50% of
cases by targeting PDGFRA [65]. In a Children’sO n c o l -
o g yG r o u pp h a s eI Is t u d yo fs e v e n t yp a t i e n t sw i t h
relapsed or refractory solid tumours treated with imati-
nib mesylate only one partial response was observed
amongst 24 patients with Ewing sarcoma/PNET, with
no responses observed in patients with osteosarcoma,
neuroblastoma, or desmoplastic small round cell
tumours [66].
CD99-directed monoclonal antibody treatment
CD99 is a surface glycoprotein encoded by the MIC2
gene that is present on Ewing sarcoma/PNET cells,
hematopoietic stem cells, testis, prostate, pancreatic cells
and gastric mucosa as well as in lymphoblastic lym-
phoma, embryonal rhabdomyosarcoma and other soft
tissue sarcomas [67]. The MIC2 gene is located on the
pseudo autosomal region at the end of the short arms of
the × and Y chromosomes [68,69]. Engagement of CD99
by a monoclonal antibody induces rapid tumour apopto-
sis through caspase independent mechanisms [70-72]. A
study that targeted CD99 with the 0662 monoclonal
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gistic efficacy against tumour growth and metastasis
with an improved survival [73]. CD99 is highly
expressed on T lymphocytes, thymocytes and hemato-
poietic cells including CD34 hematopoietic progenitor
cells. In vitro analysis of different blood cell lineages
exposed to a therapeutically effective dose of CD99
directed monoclonal antibody for the Ewing cells found
no important bone marrow toxicity, but raises theoreti-
cal concerns regarding the combination with cytotoxic
agents.
Immunotherapy
Investigators at St. Jude Children’s Research Hospital
and the University of Tennessee expanded natural killer
(NK) cells ex-vivo over 2-3 weeks in culture using co-
culture with K562-mb15-41BBL cells. Some EWS cell
lines were found to be very sensitive to allogenic NK
cells from healthy donors (median cytotoxicity 87.2% at
1:1 effector to target ratio). Blocking the NKG2D recep-
tor (an activating receptor when engaged that trigger
NK cytotoxicity) and DNAM-1 (a receptor expressed on
resting and activated NK cells and other hematopoietic
cells) attenuated cell killing. Ewing sarcoma/PNET
expresses NKG2D and DNAM-1 ligands, however a
poor correlation was observed between expression of
these ligand and cytotoxicity. These data suggest that
other mechanisms may be involved [74]. NK cells also
demonstrated anti-EWS efficacy when infused into
immunodeficient mice bearing EWS xenografts. Inter-
leukin 2 was co-administered to prolong the survival of
NK cells and multiple infusions were administered to
optimize tumour directed cytotoxicity. The role of
immunotherapies remains to be established in clinical
studies.
TRAIL (Tumour Necrosis Factor (TNF)-Related Apoptosis-
Inducing Ligand)
The TNF receptor super family is a principle regulator
of apoptosis and TNF- related apoptosis-inducing ligand
(TRAIL) induces apoptosis in Ewing sarcoma/PNET
cells. Seventy percent of these cells express the TRAIL
death receptors DR4 and DR5s are very sensitive to
TRAIL-induced caspase-8-mediated apoptosis [75].
Furthermore, in an in vivo model of Ewing sarcoma, a
cationic lipid vector was used to deliver TRAIL resulting
in growth inhibition. Although conceptually appealing,
treatment efficacy may be ameliorated by cellular resis-
tance due to TRAIL pathway signalling dysfunctions,
such as imbalances in death/decoy receptors or c-FLIP
up regulation [76,77]. Furthermore, TRAIL is expressed
in a range of normal tissues potentially leading to non-
specific tumour targeting with concomitant treatment
toxicities. Interferons can lead to the induction of
TRAIL and preclinical models have demonstrated strong
inhibition of Ewing tumour/PNET xenograft growth by
the combination of human interferon-alpha or inter-
feron-beta with ifosfamide [78-81].
Histone Deacetylase (HDAC) Inhibitors
Inhibition of histone deacetylase affects acetylation of
histones and other proteins, resulting in transcriptional
de-repression of tumour suppressor genes. This latter
effect was exemplified in a xenograft model in which
the HDAC inhibitor MS-27-275 was able to induce and
increase TGF-b receptor 2 mRNA, thereby restoring
TGF- b signalling and inhibition of ES cell growth [82].
Other genes, including the histone methyltransferase
enhancer of Zeste Homologue 2 (EZH2), mediate gene
silencing and are dependent on histone deacetylase
activity. EZH2 has been found to be important for
EWS/FLI1 driven tumour growth and metastasis and
down regulation of EZH2 inhibited tumour growth in
in-vivo experiments [83]. HDAC inhibitors have also
been shown to inhibit the growth of Ewing sarcoma/
PNET cells in other reports [84,85]. However, drug
resistant clones of Ewing sarcoma/ESFTEFT with strong
resistance to HDAC inhibitors have been identified re-
enforcing the imperative to continue the search for
other targeted therapeutics that have activity in Ewing
sarcoma/PNET in addition to HDAC inhibitors [86].
NKX2.2: a Transcriptional Repressor in Ewing Sarcoma/
PNET
NKX2.2 is a transcription factor that contains a tran-
scriptional repressor domain, and is a EWS/FLI target.
Using microarray analysis, NKX2.2 down-regulates
genes that overlap with genes regulated by EWS/FLI1.
The DNA repressor domain in NKX2.2 was necessary
for oncogenesis in Ewing sarcoma/PNET, and is prob-
ably mediated by histone deacetylase complexes. This
observation led to studies using the HDAC inhibitor,
vorinostat. The transcription profile of A673 Ewing sar-
coma cells following treatment with vorinostat was com-
pared with cells in which NKX2.2 was knocked down,
and showed considerable overlap (P < 0.001). Effectively
vorinostat reverses the NKX2.2 mediated transcription
signature [87]. These gene sets involve mesenchymal dif-
ferentiation, neurogenesis (including the NKX2.2 gene),
extracellular matrix and cytoskeleton genes and those
involved in angiogenesis, and also overlap with genes
discriminating between Ewing sarcoma/PNET cells and
mesenchymal stem cells.
Other Kinase Inhibitors
EWS-FLI1 also regulates levels of cell cycle regulators.
In Ewing sarcoma/PNET cell lines, cyclin dependent
kinase 4 (CDK4), cyclin D1, Rb, p27
KIP1 and c-Myc
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KIP2,
p15INK4B and p14ARF demonstrated undetectable or
low expression levels. Inducible expression of EWS-FLI-
1 led to up-regulation of c-Myc and marked down-regu-
lation of p57
KIP2 [88]. p16
INK4a status predicted 2-year
survival amongst patients with Ewing sarcoma/PNET (P
< .001) [89]. Also cyclin-dependent kinase 2 (CDK2)
was over-expressed in patients with poor outcomes in a
microarray-based study [90]. Cyclin E is one of the
genes regulated by the EWS-FLI1 protein. The Cyclin E/
CDK2 complex phosphorylates and inactivates the key
cell cycle regulator and tumour suppressor, the retino-
blastoma protein. The small molecule pan-cyclin depen-
dent kinase inhibitor, flavopiridol, efficiently suppresses
cell growth in vitro and in vivo in ESFT cells [91]. Fla-
vopiridol induces apoptosis and inhibit tumor growth in
drug-resistant Ewing sarcoma/PNET cells, by inducing
the cleavage of poly-ADP-ribose polymerase (PARP),
which is required for homologous recombination of
DNA base mismatches [92]. Flavopiridol has also been
found to increase the ratio of the pro-apoptotic protein
level (Bax) to the anti-apoptotic protein level (Bcl-2 and
Bcl-X (L)) [93]. The paediatric preclinical testing pro-
gram (PPTP) released results in 2010 of initial tests of
the small molecule Aurora Kinase A (AURKA) inhibitor
MLN8237 using the PPTP in vitro and in vivo panel.
AURKA is important for centrosome maturation and
spindle formation during mitosis. MLN8237 inhibited
the growth of the majority of the in vivo panel cell lines
that included five Ewing sarcoma/PNET lines. Of the
Ewing sarcoma/PNET cell lines that were evaluated in
xenograft models one had uniformly high activity for
time to event, tumour growth delay and objective
response (SK-NEP-1) and the remainder all had low or
intermediate results [94].
Conclusion
There are two major themes emerging from a review of
molecular pathology and therapeutics in Ewing sar-
coma/PNET. Firstly, risk-adapted conventional treat-
ment may be important, particularly as a high
proportion of cases of Ewing sarcoma/PNET occur in
the paediatric age group where long term treatment
related adverse sequelae have important survivorship
implications. For example, in the Euro-EWING 99 Trial,
age, tumour volume and extent of metastatic spread
where found to be prognostic risk factors for patients
with primary disseminated multifocal Ewing sarcoma/
PNET treated with intensive multimodal therapy. Var-
ious molecular markers of prognosis have recently been
identified, including BMI-1 expression as well as prog-
nostic gene expression signatures, which may be used to
guide therapy [95]. Unlike Hodgkin lymphoma, current
cure rates for limited stage Ewing sarcoma/PNET with
conventional therapy suggest it is unlikely that there will
be an appetite for reduced dose intensity. The major
o p p o r t u n i t yw i l lb et oi d e n t i f yt h o s ea ts i g n i f i c a n t l y
increased risk, who might benefit from dose-intensifica-
tion. Secondly, Ewing sarcoma/PNET is an area where
the potential exists – notwithstanding the different tech-
nical challenges – for targeted therapeutics to impact
upon advanced or relapsed disease [96]. There are nat-
ural challenges in development of novel therapeutic
approaches in Ewing sarcoma/PNET. The low incidence
rate probably presents the most significant obstacle to
improving the outcome for patients diagnosed with
Ewing sarcoma as it is a comparatively unattractive area
economically for drug development. Nonetheless, the
rapid accrual to the R1507 SARC Ewing sarcoma study
showed that, with optimism and global collaboration,
large numbers of patients can be accrued in short time-
frames. Considering the demographics, high lethality,
and defined molecular pathogenesis, targeted therapeu-
tics of Ewing sarcoma/PNET family of tumour is an
area of importance for collaborative international clinical
trials.
Author details
1Department of Medical Oncology, St. Vincent’s University Hospital, Dublin,
Ireland.
2Sarcoma Service, Department of Cancer Medicine, Peter MacCallum
Cancer Centre, Melbourne, Victoria, Australia.
Authors’ contributions
FCK conceived the manuscript aims, reviewed the literature and wrote the
manuscript. DMT wrote and edited the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 November 2011 Accepted: 1 February 2012
Published: 1 February 2012
References
1. Rodriguez-Galindo C, Spunt SL, Pappo AS: Treatment of Ewing sarcoma
family of tumours: current status and outlook for the future. Med Pediatr
Oncol 2003, 40(5):276-87.
2. DeVita Hellman, Rosenberg’s Cancer: Principles & Practice of Oncology. In
Cancer: Principles & Practice Edited by: Vincent T DeVita, Theodore S
Lawrence Steven A Rosenberg, Ronald A DePinho, Robert A Weinberg .
3. Esiashvili N, Goodman M, Marcus RB Jr: Changes in incidence and survival
of Ewing sarcoma patients over the past 3 decades: Surveillance
Epidemiology and End Results data. J Pediatr Hematol Oncol 2008,
30(6):425-30.
4. Wasilewski-Masker K, Liu Q, Yasui Y, Leisenring W, Meacham LR,
Hammond S, Meadows AT, Robison LL, Mertens AC: Late recurrence in
pediatric cancer: a report from the Childhood Cancer Survivor Study. J
Natl Cancer Inst 2009, 101(24):1709-20.
5. Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL,
Smith SM, Stovall M, Hammond S, Robison LL, Oeffinger KC: Long-term
survivors of childhood Ewing sarcoma: report from the childhood cancer
survivor study. J Natl Cancer Inst 2010, 102(16):1272-83, Epub 2010 Jul 23.
6. Suvà ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suvà D,
Clément V, Provero P, Cironi L, Osterheld MC, Guillou L, Stamenkovic I:
Identification of cancer stem cells in Ewing sarcoma. Cancer Res 2009,
69(5):1776-81, Epub 2009 Feb 10.
Kelleher and Thomas Clinical Sarcoma Research 2012, 2:6
http://www.clinicalsarcomaresearch.com/content/2/1/6
Page 11 of 147. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O:
Mesenchymal stem cell features of Ewing tumours. Cancer Cell 2007,
11(5):421-9.
8. Pizzo APhilip, David G: Poplack Principles and Practice of Pediatric
Oncology., 6, ISBN 978-1-60547-682-7.
9. Balamuth NJ, Womer RB: Ewing sarcoma. Lancet Oncol 2010, 11(2):184-92.
10. Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H,
Craft AW: Prognostic factors in Ewing’s tumour of bone: analysis of 975
patients from the European Intergroup Cooperative Ewing’s Sarcoma
Study Group. J Clin Oncol 2000, 18(17):3108-14.
11. ESMO clinical recommendations, Paulussen M, Bielack S, Jürgens H,
Casali PG, On behalf of the ESMO Guidelines Working Group: Ewing’s
sarcoma of the bone: ESMO Clinical Recommendations for diagnosis,
treatment and follow-up. Ann Oncol 2009, 20(suppl 4):iv140-iv142.
12. Bielack SS, Kohler G: A patient with two Ewing sarcomas with distinct
EWS fusion transcripts. NEJM 2004, 350:p1364, 13 March 25.
13. Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G,
Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G,
Brownhill SC, Nesslböck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW,
Jürgens H, Kovar H: Impact of EWS-ETS fusion type on disease
progression in Ewing’s sarcoma/peripheral primitive neuroectodermal
tumour: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
J Clin Oncol 2010, 28(12):1982-8, Epub 2010 Mar 22.
14. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F,
Gatterer-Menz I, Smith TL, Jürgens H, Gadner H, Kovar H: Does expression
of different EWS chimeric transcripts define clinically distinct risk groups
of Ewing tumour patients? J Clin Oncol 1996, 14(4):1245-51.
15. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL,
Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J,
Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M:
EWS-FLI1 fusion transcript structure is an independent determinant of
prognosis in Ewing’s sarcoma. J Clin Oncol 1998, 16(4):1248-55.
16. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD,
Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER: Current
treatment protocols have eliminated the prognostic advantage of type
1 fusions in Ewing sarcoma: a report from the Children’s Oncology
Group. J Clin Oncol 2010, 28(12):1989-94, Epub 2010 Mar 22.
17. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ,
Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S,
Rausen AR, Vietti TJ, Miser JS: Addition of ifosfamide and etoposide to
standard chemotherapy for Ewing sarcoma and primitive
neuroectodermal tumour of bone. N Engl J Med 2003, 348(8):694-701.
18. Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A,
Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den,
Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A,
Jürgens H: European Intergroup Cooperative Ewing Sarcoma Study-92.
Results of the EICESS-92 Study: two randomized trials of Ewing sarcoma
treatment–cyclophosphamide compared with ifosfamide in standard-risk
patients and assessment of benefit of etoposide added to standard
treatment in high-risk patients. J Clin Oncol 2008, 26(27):4385-93.
19. Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O,
van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jürgens H:
Primary disseminated multifocal Ewing sarcoma: results of the Euro-
EWING 99 trial. Clin Oncol 2010, 28(20):3284-91, Epub 2010 Jun 14.
20. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M,
Marina N, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A,
Miser J, Meyer J, Arndt CA, Sailer S, Marcus K, Perlman E, Dickman P,
Grier HE: Dose-intensified compared with standard chemotherapy for
nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology
Group Study. J Clin Oncol 2009, 27(15):2536-41, Epub 2009 Apr 6.
21. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS: Survival after
recurrence of Ewing sarcoma family of tumours. J Clin Oncol 2005,
23(19):4354-62, Epub 2005 Mar 21.
22. Ladenstein R, Lasset C, Pinkerton R, et al: Impact of megatherapy in
children with high-risk Ewing’s tumours in complete remission: A report
from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995,
15:697-705.
23. Marina N, Meyers PA: High-dose therapy and stem-cell rescue for Ewing’s
family of tumours in second remission. J Clin Oncol 2005, 23(19):4262-4,
Epub 2005 Mar 21.
24. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA: Ewing
sarcoma: standard and experimental treatment options. Curr Treat
Options Oncol 2009, 10(1-2):126-40, Epub 2009 Jun 17.
25. Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP,
Meyers PA: Irinotecan and temozolomide for Ewing sarcoma: the
Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009,
53(6):1029-34.
26. Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H:
Topotecan and cyclophosphamide in patients with refractory or
relapsed Ewing tumors. Pediatr Blood Cancer 2006, 47(6):795-800.
27. Ferrari S, del Prever AB, Palmerini E, Staals E, Berta M, Balladelli A, Picci P,
Fagioli F, Bacci G, Vanel D: Response to high-dose ifosfamide in patients
with advanced/recurrent Ewing sarcoma. P ediatr Blood Cancer 2009,
52(5):581-4.
28. Dileo P, Grosso F, Casanova M, Jimeno J, Marsoni S, Sanfilippo R, Podda M,
Ferrari S, Bertulli R, Casali PG: Trabectedin in metastatic Ewin’s family
tumours patients progressing after standard chemotherapy. Journal of
Clinical Oncology, 2007 ASCO Annual Meeting Proceedings 2007, 25(18S
(June 20 Supplement)):10040.
29. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y: EWS-Fli1 antisense
oligodeoxynucleotide inhibits proliferation of human Ewing sarcoma
and primitive neuroectodermal tumour cells. J Clin Invest 1997,
99(2):239-47.
30. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-
specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small
interfering RNA inhibits tumour growth in a murine model of metastatic
Ewing sarcoma. Cancer Res 2005, 65(19):8984-92.
31. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS,
Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A,
Toretsky JA: A small molecule blocking oncogenic protein EWS-FLI1
interaction with RNA helicase A inhibits growth of Ewing sarcoma. Nat
Med 2009, 15(7):750-6, Epub 2009 Jul 5.
32. Erkizan HV, Uversky VN, Toretsky JA: Oncogenic partnerships: EWS-FLI1
protein interactions initiate key pathways of Ewing sarcoma. Clin Cancer
Res 2010, 16(16):4077-83, Epub 2010 Jun 14.
33. Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM,
Notario V: Combined transcriptional and translational targeting of EWS/
FLI-1 in Ewing sarcoma. Clin Cancer Res 2006, 12(22):6781-90.
34. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT: EWS/
FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet
1997, 17(4):495-7.
35. Baliko F, Bright T, Poon R, Cohen B, Egan SE, Alman BA: Inhibition of notch
signaling induces neural differentiation in Ewing sarcoma. Am J Pathol
2007, 170(5):1686-94.
36. Prieur A, Tirode F, Cohen P, Delattre O: EWS/FLI-1 silencing and gene
profiling of Ewing cells reveal downstream oncogenic pathways and a
crucial role for repression of insulin-like growth factor binding protein 3.
Mol Cell Biol 2004, 24(16):7275-83.
37. Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding
protein-3 induces apoptosis and mediates the effects of transforming
growth factor-beta1 on programmed cell death through a p53- and IGF-
independent mechanism. J Biol Chem 1997, 272(18):12181-8.
38. Lee KW, Cohen P: Nuclear effects: unexpected intracellular actions of
insulin-like growth factor binding protein-3. J Endocrinol 2002,
175(1):33-40, Review.
39. ESMO Conference, Milan October 2010. Proferred papers. 13440 Safety and
efficacy results from a phase 1/2 study of the anti-IGF-IR antibody figitumab in
patients with refractory Ewing and osteosarcomas Heribert Juergens,
Muenster, Germany.
40. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J,
Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H,
Friberg G, Puzanov I: Phase I, pharmacokinetic, and pharmacodynamic
study of AMG 479, a fully human monoclonal antibody to insulin-like
growth factor receptor 1. J Clin Oncol 2009, 27(34):5800-7, Epub 2009 Sep
28.
41. Choy E, Digumarthy SR, Koplin SA: Case records of the Massachusetts
General Hospital. Case 36-2009. A 23-year-old man with cough,
hoarseness, and abnormalities on chest imaging. N Engl J Med 2009,
361(21):2080-7.
42. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, Picci P,
Manara MC, Baldini N: Insulin-like growth factor I receptor-mediated
Kelleher and Thomas Clinical Sarcoma Research 2012, 2:6
http://www.clinicalsarcomaresearch.com/content/2/1/6
Page 12 of 14circuit in Ewing sarcoma/peripheral neuroectodermal tumour: a possible
therapeutic target. Cancer Res 1996, 56(20):4570-4.
43. Staal A, Geertsma-Kleinekoort WM, Van Den, Bemd GJ, Buurman CJ,
Birkenhäger JC, Pols HA, Van Leeuwen JP: Regulation of osteocalcin
production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse
long bones: interaction with the bone-derived growth factors TGF-beta
and IGF-I. J Bone Miner Res 1998, 13(1):36-43.
44. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ: The insulin-like
growth factor-I receptor is required for EWS/FLI-1 transformation of
fibroblasts. J Biol Chem 1997, 272(49):30822-7.
45. Is the indication of IGFR antobodies in advanced refractory sarcoma
expanding?. ESMO Meeting Milan, Italy Jean-Yves Blay, Lyon EORTC; 2010.
46. Zhan S, Shapiro DN, Helman LJ: Loss of imprinting of IGF2 in Ewing
sarcoma. Oncogene 1995, 11(12):2503-7.
47. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM,
Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP,
Gualberto A, Scurr M, de Bono JS, Haluska P: Safety, pharmacokinetics,
and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-
751,871) in patients with sarcoma and Ewing sarcoma: a phase 1
expansion cohort study. Lancet Oncology 2010, 11:129-35.
48. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL:
Somatomedin-C mediates growth hormone negative feedback by
effects on both the hypothalamus and the pituitary. Science 1981,
212(4500):1279-81.
49. Werner H, Le Roith D: The insulin-like growth factor-I receptor signaling
pathways are important for tumorigenesis and inhibition of apoptosis.
Crit Rev Oncog 1997, 8(1):71-92.
50. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM,
Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ: AMG
479, a fully human anti-insulin-like growth factor receptor type I
monoclonal antibody, inhibits the growth and survival of pancreatic
carcinoma cells. Mol Cancer Ther 2009, 8(5):1095-105, Epub 2009 Apr 14.
51. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG,
Eid JE, Greig G, Habben K, McCarthy CD, Gore L: A phase I study of weekly
R1507, a human monoclonal antibody insulin-like growth factor-I
receptor antagonist, in patients with advanced solid tumours. Clin Cancer
Res 2010, 16(8):2458-65, Epub 2010 Apr 6.
52. Pappo AS, Patel S, Crowley J, Reinke DK, Staddon AP, Kuenkele K,
Chawla SP, Benjamin RS, Helman LJ, Baker LH: Activity of R1507, a
monoclonal antibody to the insulin-like growth factor-1 receptor
(IGF1R), in patients (pts) with recurrent or refractory Ewing sarcoma
family of tumours (ESFT): Results of a phase II SARC study. Abstract No:
10000. J Clin Oncol 2010, 28(15s), (suppl; abstr 10000).
53. Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL,
de Alava E: Insulin-like growth factor I receptor pathway inhibition by
ADW742, alone or in combination with imatinib, doxorubicin, or
vincristine, is a novel therapeutic approach in Ewing tumour. Clin Cancer
Res 2006, 12(11 Pt 1):3532-40.
54. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP,
Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM,
Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH:
R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1
Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family
of Tumors: Results of a Phase II Sarcoma Alliance for Research through
Collaboration Study. Journal of Clinical Oncology 2011.
55. de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindán FJ, Barr FG,
Ladanyi M: Association of EWS-FLI1 type 1 fusion with lower proliferative
rate in Ewing sarcoma. Am J Pathol 2000, 156(3):849-55.
56. Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, Nanni P, Oh Y,
Picci P, Scotlandi K: Insulin-like growth factor binding protein 3 as an
anticancer molecule in Ewing sarcoma. Int J Cancer 2006, 119(5):1039-46.
57. Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, Serra M,
Picci P, Scotlandi K: Contribution of MEK/MAPK and PI3-K signaling
pathway to the malignant behavior of Ewing sarcoma cells: therapeutic
prospects. Int J Cancer 2004, 108(3):358-66.
58. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A,
Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K:
Efficacy of and resistance to anti-IGF-1R therapies in Ewing sarcoma is
dependent on insulin receptor signaling. Oncogene 2011.
59. Maki RG: Small is beautiful: insulin-like growth factors and their role in
growth, development, and cancer. J Clin Oncol 2010, 28(33):4985-95, Epub
2010 Oct 25.
60. Paul E, Thiele E: Efficacy of sirolimus in treating tuberous sclerosis and
lymphangioleiomyomatosis. N Eng J Med 358(2):190-192.
61. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM,
Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus
for angiomyolipoma in tuberous sclerosis complex or
lymphangioleiomyomatosis. N Engl J Med 2008, 358(2):140-51.
62. mTOR inhibitors: From Lymphangioleiomyomatosis to Where? Paolo
Casali, Milan, Italy, ESMO Conference 2010 Milan.
63. Mateo-Lozano S, Tirado OM, Notario V: Rapamycin induces the fusion-type
independent downregulation of the EWS/FLI-1 proteins and inhibits
Ewing sarcoma cell proliferation. Oncogene 2003, 22(58):9282-7.
64. Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK: Protein
expression of KIT and gene mutation of c-kit and PDGFRs in Ewing
sarcomas. Pathol Res Pract 2007, 203(3):127-34, Epub 2007 Feb 12.
65. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-
Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P,
van Oosterom AT, Schuetze SM: European Organisation for Research and
Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest
Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma
protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol
2010, 28(10):1772-9, Epub 2010 Mar 1.
66. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM,
Adamson PC: A phase II study of imatinib mesylate in children with
refractory or relapsed solid tumours: a Children’s Oncology Group study.
Pediatr Blood Cancer 2008, 50(2):254-8.
67. Principles and Practice of Paediatric Oncology: In Ewing sarcoma family of
tumours Edited by: Pizzo PA, Poplack DG , 5Chapet 32:P1007.
68. Sohn HW, Choi EY, Kim SH, Lee IS, Chung DH, Sung UA, Hwang DH,
Cho SS, Jun BH, Jang JJ, Chi JG, Park SH: Engagement of CD99 induces
apoptosis through a calcineurin-independent pathway in Ewing sarcoma
cells. Am J Pathol 1998, 153(6):1937-45.
69. Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, Serra M, Lollini PL,
Nanni P, Nicoletti G, Bernard G, Bernard A, Picci P: CD99 engagement: an
effective therapeutic strategy for Ewing tumours. Cancer Res 2000,
60(18):5134-42.
70. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S,
Cenacchi G, Preda P, Lattanzi G, Nagy B, Knuutila S, Colombo MP,
Bernard A, Picci P, Scotlandi K: Molecular mechanisms of CD99-induced
caspase-independent cell death and cell-cell adhesion in Ewing sarcoma
cells: actin and zyxin as key intracellular mediators. Oncogene 2004,
23(33):5664-74.
71. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M:
MIC2 is a specific marker for Ewing sarcoma and peripheral primitive
neuroectodermal tumours. Evidence for a common histogenesis of
Ewing sarcoma and peripheral primitive neuroectodermal tumours from
MIC2 expression and specific chromosome aberration. Cancer 1991,
67(7):1886-93.
72. Alberto Pappo: Pediatric bone and soft tissue sarcoma. In Ewing sarcoma
family of tumours Edited by: Carlos Rodriguez-Galindo, Fariba Navid, Joseph
Khoury, Matthew Krasin Chapter 9:186.
73. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini PL, Curti A,
Manara MC, Benini S, Bernard A, Picci P: Targeting CD99 in association
with doxorubicin: an effective combined treatment for Ewing sarcoma.
Eur J Cancer 2006, 42(1):91-6, Epub 2005 Dec 2.
74. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D:
Cytotoxicity of activated natural killer cells against pediatric solid
tumours. Clin Cancer Res 2010, 16(15):3901-9, Epub 2010 Jun 11; Killing the
Killer: Natural Killer Cells to treat Ewing sarcoma. Ahn YO, Weigel B, Verneris
MR. Clin Cancer Res 2010 p 3819-3821; commentary.
75. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M: Ewing sarcoma family
tumours are sensitive to tumour necrosis factor-related apoptosis-
inducing ligand and express death receptor 4 and death receptor 5.
Cancer Res 2001, 61(6):2704-12.
76. Zh L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in
cancer. Cancer Gene Ther 2005, 12:228-37.
77. Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F,
Delattre O, Heymann D, Rédini F: Preclinical evidence that use of TRAIL in
Ewing sarcoma and osteosarcoma therapy inhibits tumour growth,
Kelleher and Thomas Clinical Sarcoma Research 2012, 2:6
http://www.clinicalsarcomaresearch.com/content/2/1/6
Page 13 of 14prevents osteolysis, and increases animal survival. Clin Cancer Res 2010,
16(8):2363-74, Epub 2010 Apr 6.
78. Pediatric bone and soft tissue sarcoma. Edited by: Alberto Pappo Chapter
9:P209.
79. Fanger NA, Maliszewski CR, Schooley K: Human dedritic cells mediate
cellular apoptosis via tumour necrosis factor-related apoptosis-inducing
ligand (TRAIL). J Exp Med 190:1155-1164.
80. Sancéau J, Poupon MF, Delattre O, Sastre-Garau X, Wietzerbin J: Strong
inhibition of Ewing tumour xenograft growth by combination of human
interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002,
21(50):7700-9.
81. Abadie A, Besançon F, Wietzerbin J: Type I interferon and TNFalpha
cooperate with type II interferon for TRAIL induction and triggering of
apoptosis in SK-N-MC EWING tumour cells. Oncogene 2004,
23(28):4911-20.
82. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ:
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and
in vivo antitumor activity against pediatric solid tumours. Cancer Res
2002, 62(21):6108-15.
83. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM,
Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-
Martinez L, Kovar H, Staege MS, Müller-Tidow C, Burdach S: EZH2 is a
mediator of EWS/FLI1 driven tumour growth and metastasis blocking
endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA
2009, 106(13):5324-9, Epub 2009 Mar 16.
84. Nakatani F, Tanaka K, Sakimura R, Matsumoto Y, Matsunobu T, Li X,
Hanada M, Okada T, Iwamoto Y: Identification of p21WAF1/CIP1 as a
direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003,
278(17):15105-15, Epub 2003 Jan 30.
85. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T,
Nakamura T, Matsumoto Y, Iwamoto Y: Antitumor effects of histone
deacetylase inhibitor on Ewing family tumours. Int J Cancer 2005,
116(5):784-92.
86. Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, Hanada M,
Nakamura T, Oda Y, Tsuneyoshi M, Iwamoto Y: Involvement of P-
glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of
histone deacetylase inhibitors in the drug-resistant osteosarcoma and
Ewing sarcoma cells. Int J Cancer 2006, 118(1):90-7.
87. Owen LA, Kowalewski AA, Lessnick SL: EWS/FLI mediates transcriptional
repression via NKX2.2 during oncogenic transformation in Ewing
sarcoma. PLoS One 2008, 3(4):e1965.
88. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE,
Delattre O: Analysis of the expression of cell cycle regulators in Ewing
cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene
2001, 20(25):3258-65.
89. Honoki K, Stojanovski E, McEvoy M, Fujii H, Tsujiuchi T, Kido A, Takakura Y,
Attia J: Prognostic significance of p16 INK4a alteration for Ewing
sarcoma: a meta-analysis. Cancer 2007, 110(6):1351-60.
90. Li X, Tanaka K, Nakatani F, Matsunobu T, Sakimura R, Hanada M, Okada T,
Nakamura T, Iwamoto Y: Transactivation of cyclin E gene by EWS-Fli1 and
antitumor effects of cyclin dependent kinase inhibitor on Ewing family
tumor cells. Int J Cancer 2005, 116(3):385-94.
91. Li Y, Tanaka K, Li X, Okada T, Nakamura T, Takasaki M, Yamamoto S, Oda Y,
Tsuneyoshi M, Iwamoto Y: Cyclin-dependent kinase inhibitor, flavopiridol,
induces apoptosis and inhibits tumor growth in drug-resistant
osteosarcoma and Ewing family tumor cells. Int J Cancer 2007,
121(6):1212-8.
92. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD,
Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ:
Ordering the cytochrome c-initiated caspase cascade: hierarchical
activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent
manner. J Cell Biol 1999, 144(2):281-92.
93. Boerner SA, Tourne ME, Kaufmann SH, Bible KC: Effect of P-glycoprotein
on flavopiridol sensitivity. Selected active or intended National Cancer
Institute clinical trials in Ewing sarcoma. Br J Cancer 2001, 84(10):1391-6.
94. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST,
Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ: Initial testing of the
aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing
Program (PPTP). Pediatr Blood Cancer 2010, 55(1):26-34.
95. Cooper A, van Doorninck J, Ji L, Russell D, Ladanyi M, Shimada H, Krailo M,
Womer RB, Hsu JH, Thomas D, Triche TJ, Sposto R, Lawlor ER: Ewing
tumors that do not overexpress BMI-1 are a distinct molecular subclass
with variant biology: a report from the Children’s Oncology Group. Clin
Cancer Res 2011, 17(1):56-66, Epub 2010 Nov 3.
96. Subbiah V, Anderson P: Targeted Therapy of Ewing Sarcoma. Sarcoma.
2011 2011, 686985, Epub 2010 Oct 31.
doi:10.1186/2045-3329-2-6
Cite this article as: Kelleher and Thomas: Molecular pathogenesis and
targeted therapeutics in Ewing sarcoma/primitive neuroectodermal
tumours. Clinical Sarcoma Research 2012 2:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kelleher and Thomas Clinical Sarcoma Research 2012, 2:6
http://www.clinicalsarcomaresearch.com/content/2/1/6
Page 14 of 14